Ophthalmic Research

Journal for Translational and Clinical Research
Retinal Pharmacotherapeutics

Editors: Quan Dong Nguyen, Eduardo B. Rodrigues, Michel Eid Farah, William F. Mieler, Diana V. Do

Contents

Foreword: Miller, J.W.

Basic Sciences in the Retina
- Evolving Knowledge in Pharmacologic Treatments of Age-Related Macular Degeneration: Soubrane Daguett, G.; Risard-Gasiorowski, S.; Massamba, N.
- Retinal Anatomy and Pathology: Gupta, M.P.; Herzlich, A.A.; Sauer, T.; Chan, C.-C.
- Retinal Biochemistry, Physiology and Cell Biology: Smith, R.L.; Sivaprasad, S.; Chong, V.
- Ocular Angiogenesis Vascular Endothelial Growth Factor and Other Factors: Rubin, R.G.; Adams, A.P.
- Ocular Immunity and Inflammation: Albini, T.A.; Davis, J.L.
- Complement Activation and Inhibition in Retinal Diseases: Kleinman, M.E.; Ambati, J.
- Genetics in Retinal Diseases: Riaz, M.; Baird, P.N.

Animal Models and Routes for Retinal Drug Delivery
- Routes for Drug Delivery to the Retina: Topical, Suprachoroidal and Intravitreal Gas Phase Delivery: Yamada, N.; Olsen, T.W.
- Microspheres and Nanotechnology for Drug Delivery: Johannesson, G.; Stefansson, E.; Lofftson, T.
- Thermo-Responsive Hydrogels for Ocular Drug Delivery: Kang-Mieler, J.J.; Mieler, W.F.

Retinal Diseases Amenable to Pharmacotherapy
- Nonneovascular Age-Related Macular Degeneration: Michels, S.; Garhofer, G.
- Neovascular Age-Related Macular Degeneration: Shao, J.; Choudhary, M.M.; Schachat, A.P.
- Diabetic Retinopathy and Diabetic Macular Edema: Cohen, S.R.; Gardner, T.W.
- Retinal Vein Occlusion: Sawada, O.; Ohji, S.
- Retinal Detachment and Proliferative Vepitrethropathy: Kwon, O.W.; Song, J.H.; Roh, M.J.
- Posterior Uveitis: Uy, H.S.; Yu-Keh, E.; Chan, P.S.
- Treatment for Macular Telangiectasia Type 2: Charbel Issa, P.; Kupietz, E.H.; Heeren, T.F.C.; Holz, F.G.
- Neovascular Glaucoma: Havemos, S.J.; Gulati, V.
- Retinal Hereditary and Degenerative/Dystrophic Diseases (Non-Age-Related Macular Degeneration): Battaglia Parodi, M.; La Spina, C.; Corradetti, G.; Berchicci, L.; Petruzi, G.; Bandello, F.

Drugs and Mechanisms in Retinal Diseases
- Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases: Rodrigues, E.B.; Farah, M.E.; Mantovani Bottos, J.; Bom Aggio, F.
- Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab: Klein, A.; Ambati, J.
- Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab: Smith, A.G.; Kaiser, P.K.
- Biologic Therapies: Anti-Tumor Necrosis Factor-α, Anti-Interleukins, Ritusmab and Others: Bhatt, N.; Tucker, W.; Sen, H.N.; Nussenblatt, R.B.
- Immunomodulatory Therapy in Uveitis: Tomkins-Netzer, O.; Talat, L.; Izmerov, F.; Sammy, A.; Lightman, S.
- The Protein Kinase C Inhibitor: Ruboxistaurin: Deissler, H.L.; Lang, G.E.
- Emixustat and Lampaluzumab: Potential Therapeutic Options for Geographic Atrophy: Jack, L.S.; Sadig, M.A.; Do, D.V.; Nguyen, Q.D.
- Ocular Gene Therapy: Campbell, J.P.; McFarland, T.J.; Stout, J.T.
- Neuroprotection and Retinal Diseases: Paulaus, Y.M.; Campbell, J.P.
- Photosensitizers and Photodynamic Therapy: Verteportin: Battaglia Parodi, M.; La Spina, C.; Berchicci, L.; Petruzi, G.; Bandello, F.
- Chemotherapy for Malignant Intraretinal Tumors: Shah, C.P.; Shields, C.L.; Shields, J.A.
- Antibiotics: Hariprasad, S.M.; Mieler, W.F.

Pharmacotherapy and Surgery
- Enzymatic Vitrectomy and Pharmacologic Vitreodynamics: Shah, A.R.; Trese, M.T.
- The Use of Vital Dyes during Vitreoretinal Surgery – Chromointervitreal: Farah, M.E.; Maia, M.; Penha, F.M.; Rodrigues, E.B.

The Last Words
- Regulatory and Economic Considerations of Retinal Drugs: Shah, A.R.; Williams, G.A.
- Value-Based Medicine and Pharmacoeconomics: Brown, G.C.; Brown, M.M.

The easiest way to order: www.karger.com/deoph
Ophthalmic Research

Journal for Translational and Clinical Research


Editor
José Cunha-Vaz, Coimbra

Associate Editors

Age-Related Macular Degeneration
José-Alain Sahel, Paris

Anterior Segment
Marie-José Tassignon, Antwerp

Epidemiology
Cécile Delcourt, Bordeaux

Genetics
Bart Leroy, Ghent

Glaucoma
M. Francesca Cordeiro, London

Health Technology
Francisco Batel Marques, Coimbra

Imaging
Tunde Peto, London

Immunology and Infectious Diseases
Dorairajan Balasubramanian, Hyderabad

Inflammation
José Manuel Benítez del Castillo, Madrid

Medical Retina
Sobha Sivaprasad, London

Molecular and Cell Biology
Francisco Ambrósio, Coimbra

Neuro-Ophthalmology and Visual Function
Birgit Lorenz, Giessen

Oncology and Pathology
Eduardo Midena, Padua

Surgery
Yuichiro Ogura, Nagoya

Educational – ESASO
Bruno Falcomatà, Reggio Calabria
Maurizio Battaglia Parodi, Milan

EVICR.net
Cecília Martinho, Coimbra

Editorial Board

J. Alio, Alicante
J. Ambati, Lexington, Ky.
A.J. Augustin, Karlsruhe
F. Bandello, Milan
A. Bringmann, Leipzig
T. Das, Hyderabad
D. Goldblum, Basel
G. Guarascia, Lugano
J. Hua, Boston, Mass.
T. Ishibashi, Fukuoka
J. Jonas, Mannheim
D. Lam, Guangzhou
C. Lobo, Coimbra
N. Osborne, Oxford

Y. Ozawa, Tokyo
M.J. Quadrado, Coimbra
M. Rehak, Berlin
G. Richard, Hamburg
S. Sarfare, Andover, Mass.
R.O. Schlingemann, Amsterdam
L. Schmetterer, Vienna
R. Silva, Coimbra
J. Smith, Adelaide, S.A.
P. Söderberg, Uppsala
J. Trevithick, London, Ont.
K. Tsubota, Tokyo
A. Wegener, Bonn
Guidelines for Authors

Submission
Only original papers written in English are considered and should be submitted using the online submission website:

www.karger.com/ore

or as an e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:

Editorial Office Ophthalmic Research
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel +41 61 306 1358
Fax +41 61 306 1434
E-Mail ore@karger.com

Types of Papers
(1) The main body of papers to be published will be Original Papers on experimental research. (2) Review Papers’ up to 30 manuscript pages will be published from invited authors and by direct submission. In both cases the manuscripts will be subject to peer reviewing. Review papers will be published free of charge. (3) Mini Reviews of up to 10 manuscript pages (double-spaced, including an abstract of max. 200 words and references) should contain an easy-to-read literature overview on a specific topic. Papers are either invited or may be submitted for consideration. Please submit your mini review online. (4) Short Communications of up to 3–4 pages dealing with new original concepts or technical approaches will be published at short notice. (5) Ophthalmic Research has a tradition in publishing Supplements which can be published under the responsibility of guest editors. Requests for such supplements should be addressed to the Editor-in-Chief.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication except in abstract form. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. Research involving live human and animal subjects must have been approved by the author’s institutional review board. Ophthalmic Research requires that in the Methods section of their manuscript the authors state that they adhered to the tenets of the Declaration of Helsinki or the NIH statement for the use of Animals in Research.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Arrangement
Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 200 words.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be sent in separate files. Tables require a heading and figures a legend, also in a separate file. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 225 mm). Black and white half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color Illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 900.00 per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:
• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com
• Include the following statement: ‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytoogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi?insert DOI number.’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author’s Choice™ (Gold Open Access) articles, see Author’s Choice™.
For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

**Funding Organizations (NIH etc.)**
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

**Page Charges**
There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 8 double-spaced manuscript pages (including abstract, tables, illustrations and references).

**Proofs**
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

**Reprints**
Orders forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

---

**ESASO Course Series**
Expert presentations made available in print

This new book series makes the essentials of the courses of the European School for Advanced Studies in Ophthalmology (ESASO) available to interested ophthalmologists, optometrists, technicians and residents all over the world. The presentations of the courses are published regularly featuring a wide range of ophthalmological topics from vitreoretinal pathology to retinal surgery, retinal diseases, cornea and refractive surgery or cataract.

**ESASO Course Series**

Vol. 6: Cornea

Editor: Güell, J.L. (Barcelona)

VIII + 128 p., 85 fig., 81 in color, 9 tab., 2015

CHF 98.00 / EUR 92.00 / USD 115.00

(soft cover)

CHF 118.00 / EUR 110.00 / USD 138.00

(online)


Vol. 5: Orbital Surgery

Editors: Medel R.; Vázquez L.M. (Barcelona)

VIII + 116 p., 87 fig., 82 in color, 3 tab., 2014

CHF 98.00 / EUR 92.00 / USD 115.00

(soft cover)

CHF 118.00 / EUR 110.00 / USD 138.00

(online)


Vol. 4: Optical Coherence Tomography

Editors: Cocos, G. (Creteil/Paris); Lonvaensten, A. (Tel Aviv); Bandello, F. (Milan)

XII + 134 p., 137 fig., 97 in color, 9 tab., 2014

CHF 98.00 / EUR 92.00 / USD 115.00

(soft cover)

CHF 118.00 / EUR 110.00 / USD 138.00

(online)


Vol. 3: Cataract

Editor: Güell, J.L. (Barcelona)

VIII + 140 p., 178 fig., 168 in color, 5 tab., 2013

CHF 98.00 / EUR 92.00 / USD 115.00

(soft cover)

CHF 118.00 / EUR 110.00 / USD 138.00

(online)


Online version for institutional purchase

Prices subject to change, VAT not included. EUR price for eurozone countries, USD price for USA and Latin America only

© 2016 S. Karger AG, Basel

E-Mail karger@karger.com

The Guidelines for Authors are available at:

www.karger.com/ore_Guidelines
Contents

See the journal website for contents
APA O
2016 Taipei
March 24 - 27

The 31st Asia-Pacific Academy of Ophthalmology Congress

in conjunction with

The 57th Annual Meeting of the Ophthalmological Society of Chinese Taipei
Orbital surgery deals with a variety of complications occurring in the eye socket comprising inflammatory diseases like thyroid-associated orbitopathy, tumors, infections, and injuries from trauma that affect eye function.

In this volume, renowned European orbital surgery experts share their professional experience and expertise. Their contributions cover basic as well as more specialized up-to-date concepts that are beneficial in the diagnosis and treatment of patients with orbital disorders.

The book offers a practical review of this complex and very interesting branch of ophthalmic plastic surgery for ophthalmology residents, ophthalmic plastic and orbital surgery fellows, ophthalmic plastic surgeons with a special interest in orbital surgery, and general ophthalmologists.

Contents

• Preface: Medel, R.; Vásquez, L.M.
• Basic Concepts in Orbital Examination: Vásquez, L.M.
• Orbital Decompression in Thyroid Eye Disease: Baldeschi, L.; Boschi, A.
• Orbital Fractures and Management of Diplopia: Morax, S.; Bok-Beaube, C.
• Approach to Diagnosis of Orbital Tumours: Medel, R.; Balaguer, Ó.
• Evisceration, Enucleation and Exenteration: Tyers, A.G.
• Anophthalmic Socket: Hintschich, C.
• Subject Index
The first ophthalmology journal dedicated exclusively to case reports

Case Reports in Ophthalmology

www.karger.com/cop

- open access
- peer-reviewed
- fast online publication

This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of ophthalmology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The submission of negative results is strongly encouraged. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information. Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.

More information at www.karger.com/cop
Review

135 Association of Two Polymorphisms, rs1061170 and rs1410996, in Complement Factor H with Age-Related Macular Degeneration in an Asian Population: A Meta-Analysis
Wu, M.; Guo, Y.; Ma, Y.; Zheng, Z.; Wang, Q.; Zhou, X. (Chongqing)

Original Papers

111 Risk Factors and Age-Related Macular Degeneration in a Mediterranean-Basin Population: The PAMDI (Prevalence of Age-Related Macular Degeneration in Italy) Study – Report 2
Piermarocchi, S. (Padua); Tognetto, D.; Piermarocchi, R. (Trieste); Masetto, M. (Abano Terme); Monterosso, G. (Schio); Segato, T.; Cavarzeran, F. (Padua); Turrini, A. (Rome); Peto, T. (London) for the PAMDI Study Group

119 Long-Term Management of RAP Lesions in Clinical Practice: Treatment Efficacy and Predictors of Functional Improvement
Marques, M.F.; Marques, J.P.; Gil, J.Q.; Costa, J.; Almeida, E.; Cachulo, M.d.L.; Pirès, I.; Figueira, J.; Silva, R. (Coimbra)

126 Retinal Phenotype following Combined Deletion of the Chemokine Receptor CCR2 and the Chemokine CX3CL1 in Mice

145 Sequential Morphological Changes in the CNV Net after Intravitreal Anti-VEGF Evaluated with OCT Angiography
Marques, J.P.; Costa, J.F.; Marques, M.; Cachulo, M.L.; Figueira, J.; Silva, R. (Coimbra)

152 Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up
Chiquet, C. (Grenoble); Bron, A.M.; Straub, M. (Dijon); Dupuy, C. (Grenoble); Isaico, R. (Dijon); Aptel, F. (Grenoble); Creuzot-Garcher, C. (Dijon)

159 Immunohistochemical Analysis of PDGFR-α, PDGFR-β and c-Abl in Retinoblastoma: Potential Therapeutic Targets
Sanft, D.-M.; Worme, M.D. (Montreal, Que.); Rielo de Moura, L. (Montreal, Que./Rio de Janeiro/São Paulo); Zoroquiain, P.; Fernandes, B.F.; Antecka, E.; Burnier, M.N., Jr. (Montreal, Que.)

163 Erratum